Top

Published in:

01-03-2019 | Lymphoma | Review Article

Hematopoietic stem cell transplantation in primary central nervous system lymphoma: a review of the literature

Authors: Daria Gaut, Gary J. Schiller

Published in: International Journal of Hematology | Issue 3/2019

Abstract

Primary central nervous system lymphoma (PCNSL) is an uncommon variant of extranodal non-Hodgkin lymphoma (NHL) with an aggressive course and worse outcomes compared with other lymphomas of similar tumor burden and histologic subtype. High-dose chemotherapy supported by autologous stem cell transplantation (HDC/ASCT) is an option for therapy for this disease in both the relapse setting and as post-remission consolidation. Data are currently limited to only several single-arm phase II trials with small sample sizes, but randomized trials are now ongoing. In this review, we discuss the efficacy, feasibility, and toxicity of HDC/ASCT for PCNSL and its role in the treatment of this aggressive malignancy, both in the first-line and relapse settings. We also bring to attention the current data on allogeneic stem cell transplantation (allo-SCT) in PCNSL.

Hoffman S, Propp JM, McCarthy BJ. Temporal trends in incidence of primary brain tumors in the United States, 1985–1999. Neuro Oncol. 2006;8(1):27–37. https://doi.org/10.1215/S1522851705000323.PubMedPubMedCentralCrossRef

Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol. 2012;14(Suppl 5):v1–49. https://doi.org/10.1093/neuonc/nos218. Suppl 5) .PubMedPubMedCentralCrossRef

Jahnke K, Thiel E, Martus P, Herrlinger U, Weller M, Fischer L, et al. Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. J Neurooncol. 2006;80(2):159–65. https://doi.org/10.1007/s11060-006-9165-6.PubMedCrossRef

Ferreri AJM, Reni M, Pasini F, Calderoni A, Tirelli U, Pivnik A, et al. A multicenter study of treatment of primary CNS lymphoma. Neurology. 2002;58(10):1513–20.PubMedCrossRef

Kasenda B, Ferreri AJM, Marturano E, Forst D, Bromberg J, Ghesquieres H, et al. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)—a systematic review and individual patient data meta-analysis. Ann Oncol. 2015;26(7):1305–13. https://doi.org/10.1093/annonc/mdv076.PubMedPubMedCentralCrossRef

Citterio G, Reni M, Gatta G, Ferreri AJM. Primary central nervous system lymphoma. Crit Rev Oncol Hematol. 2017;113:97–110. https://doi.org/10.1016/J.CRITREVONC.2017.03.019.PubMedCrossRef

Ferreri AJM. How I treat primary CNS lymphoma. Blood. 2011;118(3):510–22. https://doi.org/10.1182/blood-2011-03-321349.PubMedCrossRef

Langner-Lemercier S, Houillier C, Soussain C, Ghesquières H, Chinot O, Taillandier L, et al. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. Neuro Oncol. 2016;18(9):1297–303. https://doi.org/10.1093/neuonc/now033.PubMedPubMedCentralCrossRef

Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010;11(11):1036–47. https://doi.org/10.1016/S1470-2045(10)70229-1.PubMedCrossRef

10.

Korfel A, Thiel E, Martus P, Griesinger F, Rauch M, Röth A, et al. Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. Neurology. 2015;84(12):1242–8. https://doi.org/10.1212/WNL.0000000000001395.PubMedCrossRef

11.

Rubenstein JL, Hsi ED, Johnson JL, Jung SH, Nakashima MO, Grant B, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol. 2013;31(25):3061–8. https://doi.org/10.1200/JCO.2012.46.9957.PubMedPubMedCentralCrossRef

12.

Reni M, Ferreri AJ. Therapeutic management of refractory or relapsed primary central nervous system lymphomas. Ann Hematol. 2001;80(Suppl 3):B113–7.PubMed

13.

Deangelis LM, Iwamoto FM. An update on therapy of primary central nervous system lymphoma. Hematol Am Soc Hematol Educ Progr. 2006;2006(1):311–6. https://doi.org/10.1182/asheducation-2006.1.311.CrossRef

14.

Gerstner ER, Batchelor TT. Primary central nervous system lymphoma. Arch Neurol. 2010;67(3):291–7. https://doi.org/10.1001/archneurol.2010.3.PubMedCrossRef

15.

Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-hodgkin’s lymphoma. N Engl J Med. 1995;333(23):1540–5. https://doi.org/10.1056/NEJM199512073332305.PubMedCrossRef

16.

Soussain C, Suzan F, Hoang-Xuan K, Cassoux N, Levy V, Azar N, et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol. 2001;19(3):742–9. https://doi.org/10.1200/JCO.2001.19.3.742.PubMedCrossRef

17.

Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J Clin Oncol. 2008;26(15):2512–8. https://doi.org/10.1200/JCO.2007.13.5533.PubMedCrossRef

18.

Soussain C, Choquet S, Fourme E, Delgadillo D, Bouabdallah K, Ghesquières H, et al. Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases. Haematologica. 2012;97(11):1751–6. https://doi.org/10.3324/haematol.2011.060434.PubMedPubMedCentralCrossRef

19.

Cote GM, Hochberg EP, Muzikansky A, Hochberg FH, Drappatz J, McAfee SL, et al. Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-hodgkin lymphoma. Biol Blood Marrow Transpl. 2012;18(1):76–83. https://doi.org/10.1016/j.bbmt.2011.07.006.CrossRef

20.

Welch MR, Sauter CS, Matasar MJ, Faivre G, Weaver SA, Moskowitz CH, et al. Autologous stem cell transplant in recurrent or refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan and cyclophosphamide. Leuk Lymphoma. 2015;56(2):361–7. https://doi.org/10.3109/10428194.2014.916800.PubMedCrossRef

21.

Alimohamed N, Daly A, Owen C, Duggan P, Stewart DA. Upfront thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation for primary CNS lymphoma: a single centre experience. Leuk Lymphoma. 2012;53(5):862–7. https://doi.org/10.3109/10428194.2011.633250.PubMedCrossRef

22.

Choi MK, Kang ES, Kim DW, Ko YH, Seok H, Park JH, et al. Treatment outcome of relapsed/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation. Int J Hematol. 2013;98(3):346–54. https://doi.org/10.1007/s12185-013-1403-z.PubMedCrossRef

23.

Fischer L, Thiel E, Klasen H-A, Birkmann J, Jahnke K, Martus P, et al. Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol. 2006;17(7):1141–5. https://doi.org/10.1093/annonc/mdl070.PubMedCrossRef

24.

Reni M, Zaja F, Mason W, Perry J, Mazza E, Spina M, et al. Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer. 2007;96(6):864–7. https://doi.org/10.1038/sj.bjc.6603660.PubMedPubMedCentralCrossRef

25.

Arellano-Rodrigo E, López-Guillermo A, Bessell EM, Nomdedeu B, Montserrat E, Graus F. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Eur J Haematol. 2003;70(4):219–24.PubMedCrossRef

26.

Nguyen PL, Chakravarti A, Finkelstein DM, Hochberg FH, Batchelor TT, Loeffler JS. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol. 2005;23(7):1507–13. https://doi.org/10.1200/JCO.2005.01.161.PubMedCrossRef

27.

Reni M, Mazza E, Foppoli M, Ferreri AJM. Primary central nervous system lymphomas: salvage treatment after failure to high-dose methotrexate. Cancer Lett. 2007;258(2):165–70. https://doi.org/10.1016/J.CANLET.2007.10.009.PubMedCrossRef

28.

Plotkin SR, Betensky RA, Hochberg FH, Grossman SA, Lesser GJ, Nabors LB, et al. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res. 2004;10(17):5643–6. https://doi.org/10.1158/1078-0432.CCR-04-0159.PubMedCrossRef

29.

Illerhaus G, Marks R, Ihorst G, Guttenberger R, Ostertag C, Derigs G, et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol. 2006;24(24):3865–70. https://doi.org/10.1200/JCO.2006.06.2117.PubMedCrossRef

30.

Illerhaus G, Muller F, Feuerhake F, Schafer A-O, Ostertag C, Finke J. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica. 2008;93(1):147–8. https://doi.org/10.3324/haematol.11771.PubMedCrossRef

31.

Ferreri AJM, Cwynarski K, Pulczynski EJ, Fox CP, Schorb E, Rosèe PL, et al. Effects on survival and neurocognitive functions of whole-brain radiotherapy (WBRT) and autologous stem cell transplantation (ASCT) as consolidation options after high-dose methotrexate-based chemoimmunotherapy in patients with newly diagnosed primary CNS lymphoma (PCNSL): results of the second randomization of the IELSG32 trial. Blood. 2016;128(22):511.

32.

Illerhaus G, Kasenda B, Ihorst G, Egerer G, Lamprecht M, Keller U, et al. High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. Lancet Haematol. 2016;3(8):e388–97. https://doi.org/10.1016/S2352-3026(16)30050-3.PubMedCrossRef

33.

Bojic M, Berghoff AS, Troch M, Agis H, Sperr WR, Widhalm G, et al. Haematopoietic stem cell transplantation for treatment of primary CNS lymphoma: single-centre experience and literature review. Eur J Haematol. 2015;95(1):75–82. https://doi.org/10.1111/ejh.12482.PubMedCrossRef

34.

Alvarnas JC, Negrin RS, Horning SJ, Hu WW, Long GD, Schriber JR, et al. High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin’s lymphoma. Biol Blood Marrow Transpl. 2000;6(3A):352–8.CrossRef

35.

Montemurro M, Kiefer T, Schüler F, Al-Ali HK, Wolf HH, Herbst R, et al. Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study. Ann Oncol. 2006;18(4):665–71. https://doi.org/10.1093/annonc/mdl458.PubMedCrossRef

36.

Kiefer T, Hirt C, Späth C, Schüler F, Al-Ali HK, Wolf HH, et al. Long-term follow-up of high-dose chemotherapy with autologous stem-cell transplantation and response-adapted whole-brain radiotherapy for newly diagnosed primary CNS lymphoma: results of the multicenter Ostdeutsche Studiengruppe Hamatologie und Onkologie OSHO-53 phase II study. Ann Oncol. 2012;23(7):1809–12. https://doi.org/10.1093/annonc/mdr553.PubMedCrossRef

37.

Yoon DH, Lee DH, Choi DR, Sohn BS, Kim S, Kim SW, et al. Feasibility of BU, CY and etoposide (BUCYE) and auto-SCT in patients with newly diagnosed primary CNS lymphoma: a single-center experience. Bone Marrow Transpl. 2011;46(1):105–9. https://doi.org/10.1038/bmt.2010.71.CrossRef

38.

Kasenda B, Schorb E, Fritsch K, Finke J, Illerhaus G. Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma—a long-term follow-up study. Ann Oncol. 2012;23(10):2670–5. https://doi.org/10.1093/annonc/mds059.PubMedCrossRef

39.

Abrey LE, Moskowitz CH, Mason WP, Crump M, Stewart D, Forsyth P, et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol. 2003;21(22):4151–6. https://doi.org/10.1200/JCO.2003.05.024.PubMedCrossRef

40.

Miyao K, Sakemura R, Imai K, Sakai T, Tsushita N, Kato T, et al. Upfront autologous stem-cell transplantation with melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED) in patients with newly diagnosed primary central nervous system lymphoma. Int J Hematol. 2014;100(2):152–8. https://doi.org/10.1007/s12185-014-1608-9.PubMedCrossRef

41.

Scordo M, Bhatt V, Hsu M, Omuro AM, Matasar MJ, DeAngelis LM, et al. A comprehensive assessment of toxicities in patients with central nervous system lymphoma undergoing autologous stem cell transplantation using thiotepa, busulfan, and cyclophosphamide conditioning. Biol Blood Marrow Transpl. 2017;23(1):38–43. https://doi.org/10.1016/j.bbmt.2016.09.024.CrossRef

42.

Brevet M, Garidi R, Gruson B, Royer B, Vaida I, Damaj G. First-line autologous stem cell transplantation in primary CNS lymphoma. Eur J Haematol. 2005;75(4):288–92. https://doi.org/10.1111/j.1600-0609.2005.00508.x.PubMedCrossRef

43.

Colombat P, Lemevel A, Bertrand P, Delwail V, Rachieru P, Brion A, et al. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transpl. 2006;38(6):417–20. https://doi.org/10.1038/sj.bmt.1705452.CrossRef

44.

Omuro A, Correa DD, DeAngelis LM, Moskowitz CH, Matasar MJ, Kaley TJ, et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015;125(9):1403–10. https://doi.org/10.1182/blood-2014-10-604561.PubMedPubMedCentralCrossRef

45.

DeFilipp Z, Li S, El-Jawahri A, Armand P, Nayak L, Wang N, et al. High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission. Cancer. 2017;123(16):3073–9. https://doi.org/10.1002/cncr.30695.PubMedCrossRef

46.

Chen Y-B, Batchelor T, Li S, Hochberg E, Brezina M, Jones S, et al. Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma. Cancer. 2015;121(2):226–33. https://doi.org/10.1002/cncr.29023.PubMedCrossRef

47.

Houillier C, Taillandier L, Lamy T, Chinot O, Molucon-Chabrot C, Soubeyran P, et al. Whole brain radiotherapy (WBRT) versus intensive chemotherapy with haematopoietic stem cell rescue (IC + HCR) for primary central nervous system lymphoma (PCNSL) in young patients: an intergroup anocef-goelams randomized phase II trial (PRECIS). Blood. 2016;128(22):782.

48.

Cheng T, Forsyth P, Chaudhry A, Morris D, Glück S, Russell JA, et al. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transpl. 2003;31(8):679–85. https://doi.org/10.1038/sj.bmt.1703917.CrossRef

49.

Puig N, De La Rubia J, Remigia MJ, Jarque I, Martín G, Cupelli L, et al. Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation. Leuk Lymphoma. 2006;47(8):1488–94. https://doi.org/10.1080/10428190500527769.PubMedCrossRef

50.

Lahoud OB, Sauter CS, Hamlin PA, Dahi PB. High-dose chemotherapy and autologous stem cell transplant in older patients with lymphoma. Curr Oncol Rep. 2015;17(9):42. https://doi.org/10.1007/s11912-015-0465-x.PubMedPubMedCentralCrossRef

51.

Wiebe VJ, Smith BR, DeGregorio MW, Rappeport JM. Pharmacology of agents used in bone marrow transplant conditioning regimens. Crit Rev Oncol Hematol. 1992;13(3):241–70.PubMedCrossRef

52.

Muldoon LL, Soussain C, Jahnke K, Johanson C, Siegal T, Smith QR, et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol. 2007;25(16):2295–305. https://doi.org/10.1200/JCO.2006.09.9861.PubMedCrossRef

53.

Ferreri AJM, Illerhaus G. The role of autologous stem cell transplantation in primary central nervous system lymphoma. Blood. 2016;127(13):1642–9. https://doi.org/10.1182/blood-2015-10-636340.PubMedCrossRef

54.

Schorb E, Kasenda B, Atta J, Kaun S, Morgner A, Hess G, et al. Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation. Haematologica. 2013;98(5):765–70. https://doi.org/10.3324/haematol.2012.076075.PubMedPubMedCentralCrossRef

55.

Hande KR, Wedlund PJ, Noone RM, Wilkinson GR, Greco FA, Wolff SN. Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. Cancer Res. 1984;44(1):379–82.PubMed

56.

Motl S, Zhuang Y, Waters CM, Stewart CF. Pharmacokinetic considerations in the treatment of CNS tumours. Clin Pharmacokinet. 2006;45(9):871–903. https://doi.org/10.2165/00003088-200645090-00002.PubMedCrossRef

57.

Graul EH, Schaumlöffel E, Hundeshagen H, Wilmanns H, Simon G. Metabolism of radioactive cyclophosphamide. Animal tests and clinical studies. Cancer. 1967;20(5):896–9.PubMedCrossRef

58.

Wieduwilt MJ, Valles F, Issa S, Behler CM, Hwang J, McDermott M, et al. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. Clin Cancer Res. 2012;18(4):1146–55. https://doi.org/10.1158/1078-0432.CCR-11-0625.PubMedPubMedCentralCrossRef

59.

Fraser E, Gruenberg K, Rubenstein JL. New approaches in primary central nervous system lymphoma. Chin Clin Oncol. 2015;4(1):11. https://doi.org/10.3978/j.issn.2304-3865.2015.02.01.PubMedPubMedCentralCrossRef

60.

DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ, Radiation Therapy Oncology Group Study 93 – 10. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93–10. J Clin Oncol. 2002;20(24):4643–8. https://doi.org/10.1200/JCO.2002.11.013.PubMedCrossRef

61.

Morris PG, Correa DD, Yahalom J, Raizer JJ, Schiff D, Grant B, et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol. 2013;31(31):3971–9. https://doi.org/10.1200/JCO.2013.50.4910.PubMedPubMedCentralCrossRef

62.

Bhatt VR. Allogeneic stem cell transplantation for non-hodgkin lymphoma. Curr Hematol Malig Rep. 2016;11(3):196–207. https://doi.org/10.1007/s11899-016-0319-0.PubMedCrossRef

63.

Atilla E, Sahin U, Atilla PA, Merter M, Ozyurek E, Ceyhan K, et al. Allogeneic stem cell transplantation for relapsed primary central nervous system lymphoma: is it feasible? Hematol Oncol Stem Cell Ther. 2018. https://doi.org/10.1016/J.HEMONC.2018.02.001.CrossRefPubMed

64.

Varadi G, Or R, Kapelushnik J, Naparstek E, Nagler A, Brautbar C, et al. Graft-versus-lymphoma effect after allogeneic peripheral blood stem cell transplantation for primary central nervous system lymphoma. Leuk Lymphoma. 1999;34(1–2):185–90. https://doi.org/10.3109/10428199909083396.PubMedCrossRef

65.

Carson MJ, Doose JM, Melchior B, Schmid CD, Ploix CC. CNS immune privilege: hiding in plain sight. Immunol Rev. 2006;213:48–65. https://doi.org/10.1111/j.1600-065X.2006.00441.x.PubMedPubMedCentralCrossRef

Title: Hematopoietic stem cell transplantation in primary central nervous system lymphoma: a review of the literature
Authors: Daria Gaut
Gary J. Schiller
Publication date: 01-03-2019
Publisher: Springer Japan
Keywords: Lymphoma
Rituximab
Rituximab
Stem Cell Transplantation
Stem Cell Transplantion
Stem Cell Transplantation
Cytostatic Therapy
Published in: International Journal of Hematology / Issue 3/2019
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-019-02594-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2019

Association of high levels of plasma OX40 with acute adult T-cell leukemia

Inhibitor development, safety and efficacy of Advate® among previously treated patients with hemophilia A in a postmarketing surveillance in Japan

A case of pancytopenia and hypercellular bone marrow: when family history can suggest the diagnosis

Limited efficacy of high-dose methotrexate in patients with neurolymphomatosis

Clinical features of dyskeratosis congenita in mainland China: case reports and literature review

Complete remission of pure white cell aplasia associated with thymoma after thymectomy and cyclosporine administration

Keynote webinar | Spotlight on antibody–drug conjugates in cancer